Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 3/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 17/20 | 0.54 |
| ▸ | KIT | P10721 | 4/20 | 0.48 |
| ▸ | FLT3 | P36888 | 4/20 | 0.48 |
| ▸ | CSF1R | P07333 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12049454 | 0.90 | MAPK7 (0.61) | MAPK7PDGFRBKITFLT3CSF1R | |
| SCHEMBL14601828 | 0.90 | MAPK7 (0.56) | MAPK7PDGFRBKITFLT3CSF1R | |
| SCHEMBL12060839 | 0.88 | MAPK7 (0.54) | MAPK7PDGFRBKITFLT3CSF1R | |
| SCHEMBL12048868 | 0.87 | PDGFRB (0.55) | MAPK7PDGFRBKITFLT3CSF1R | |
| SCHEMBL12048856 | 0.86 | MAPK7 (0.76) | MAPK7PDGFRBKITFLT3CSF1R | |
| SCHEMBL12049280 | 0.85 | PDGFRB (0.54) | MAPK7PDGFRBKITFLT3CSF1R | |
| SCHEMBL12048915 | 0.85 | PDGFRB (0.61) | MAPK7PDGFRBKITFLT3CSF1R | |
| SCHEMBL12060669 | 0.84 | PDGFRB (0.52) | MAPK7PDGFRBKITFLT3CSF1R | |
| SCHEMBL12048879 | 0.84 | MAPK7 (0.53) | MAPK7PDGFRBKITFLT3CSF1R | |
| SCHEMBL12060998 | 0.84 | MAPK7 (0.51) | MAPK7PDGFRBKITFLT3CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071768-B2 | Alkylquinoline and alkylquinazoline kinase modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-8071768-B2 | Alkylquinoline and alkylquinazoline kinase modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| CN-101291922-A | Alkylquinoline and alkylquinazoline kinase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2008-10-22 | — | — | CN | disclosed |
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | FLT3, MCL1, CDC42BPG | MAPK7 957/4885PDGFRB 224/4885KIT 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.